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Measuring quality of life in muscular
dystrophy
ABSTRACT
Objectives: The objectives of this study were to develop a conceptual model of quality of life (QOL)
in muscular dystrophies (MDs) and review existing QOL measures for use in the MD population.
Methods: Our model for QOL among individuals with MD was developed based on a modified Del-
phi process, literature review, and input from patients and patient advocacy organizations. Scales
that have been used to measure QOL among patients with MD were identified through a literature
review and evaluated using the COSMIN (Consensus-Based Standards for the Selection of Health
Measurement Instruments) checklist.
Results: The Comprehensive Model of QOL in MD (CMQM) captures 3 broad domains of QOL
(physical, psychological, and social), includes factors influencing self-reported QOL (disease-
related factors, support/resources, and expectations/aspirations), and places these concepts
within the context of the life course. The literature review identified 15 QOL scales (9 adult
and 6 pediatric) that have been applied to patients with MD. Very few studies reported reliability
data, and none included data on responsiveness of the measures to change in disease progres-
sion, a necessary psychometric property for measures included in treatment and intervention
studies. No scales captured all QOL domains identified in the CMQM model.
Conclusions: Additional scale development research is needed to enhance assessment of QOL for
individuals with MD. Item banking and computerized adaptive assessment would be particularly
beneficial by allowing the scale to be tailored to each individual, thereby minimizing respondent
burden. Neurology® 2015;84:1034–1042
GLOSSARY
CMQM 5 Comprehensive Model of Quality of Life in Muscular Dystrophy; COSMIN 5 Consensus-Based Standards for the
Selection of Health Measurement Instruments; HRQOL 5 health-related quality of life; ICF 5 International Classification of
Functioning, Disability and Health; INQoL 5 Individualized Neuromuscular Quality of Life; MD 5 muscular dystrophy;
PedsQL 5 Pediatric Quality of Life Inventory; PROMIS 5 Patient-Reported Outcomes Measurement Information System;
QOL 5 quality of life; TAAQoL 5 TNO-AZL Questionnaire for Adult’s Quality of Life; WHO 5 World Health Organization.
Muscular dystrophies (MDs) are a clinically diverse group of debilitating diseases characterized
by progressive muscle weakness that can affect not only mobility but respiration and cardiac
function as well. These diseases have varying ages of onset and severity of disease progression
(figure 1; see reference 1 for a review).
Older age, longer illness duration, and greater disease severity are associated with lower per-
ceived health-related quality of life (HRQOL) among individuals with MD.2–6,e1,e2 However,
treatments such as corticosteroids have been linked with improved physical functioning, greater
life expectancy, and better HRQOL in some forms of MD.2,5,6,e3,e4
Reliable and valid quality of life (QOL) measures are needed to assess the impact of MD on
QOL and to accurately measure changes in QOL due to interventions and treatments. How-
ever, existing QOL measures and models do not capture all components of QOL that are mean-
ingful to individuals with MD. For example, stakeholders (patients/families, clinicians,
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researchers, and advocates) participating in the
2011 Centers for Disease Control and Preven-
tion’s meeting on priorities for MD research
identified significant gaps in existing QOL
models, noting that they do not adequately
capture emotional effects of disease, personal
sense of meaningfulness, participation in soci-
ety, access to care, and QOL issues at transi-
tional points in a progressive disease.
The current study introduces a new con-
ceptual model of QOL in MD based on stake-
holder input and a literature review and
outlines the domains and psychometric prop-
erties of existing QOL measures applicable
to adults and children with MD.
METHODS To facilitate measurement of QOL that is respon-
sive to the unique experiences of individuals living with MD, we
undertook the multistep process outlined in figure 2. First, we
developed an expanded conceptual model of QOL in MD, using
a modified Delphi process. We reviewed existing QOL measures
applied to neuromuscular disorders, including MD, and com-
piled a list of 104 possible QOL domains for inclusion in the
model (table e-1 on the Neurology® Web site at Neurology.org).
A diverse group of 12 stakeholders (patient/family members,
clinicians, advocates, and researchers) then independently
ranked these domains on a 4-point scale (critical, important,
somewhat important, or not essential) regarding importance to
measuring QOL in MD. The group reviewed the rankings during
a 2-day, in-person meeting in July 2013 and reached a consensus
on which domains should be included in the model, which was
then refined through a series of additional group discussions.
After developing the conceptual model and identifying
important components of QOL in MD, we examined the
properties of existing QOL measures in individuals with MD.
To identify studies that have used these measures, we conducted
a search of PubMed, PsycINFO, and Embase for English
language articles published between January 1, 1990, and
November 22, 2013, with the following search terms: Muscular
Dystrophy AND quality of life AND (measure OR scale OR
assessment OR survey OR questionnaire OR instrument OR
inventory). Additional articles and measures were identified
through a review of the bibliographies of the articles resulting
from the database search.
We reviewed the identified measures using the Consensus-
Based Standards for the Selection of Health Measurement Instru-
ments (COSMIN) checklist, a rigorous, standardized tool for as-
sessing psychometric properties of patient-reported outcomes.7
The checklist includes 10 broad categories of psychometric prop-
erties: internal consistency, reliability, measurement error, con-
tent validity, structural validity, hypotheses testing, cross-cultural
validity, criterion validity, responsiveness, and interpretability.
We briefly summarize here the psychometric properties of each
measure among individuals with MD as reported in the articles.
Because of limited information on some COSMIN categories
reported in the current studies, we have condensed the informa-
tion into 2 categories: reliability/internal consistency and validity.
When providing mean scores, if available, we have used individ-
uals’ self-reports rather than proxies’ reports.
RESULTS QOL model. Based on the Delphi process,
literature review, and input from individuals with
Figure 1 Progression from disease onset to death throughout the life course for 9 types of muscular dystrophies (MDs)
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MD and advocacy organizations, we developed the
Comprehensive Model of QOL in Muscular Dystro-
phy (CMQM) shown in figure 3. The CMQM por-
trays the impact of MD on an individual’s QOL and
the related construct of well-being. Overall, the
CMQM is consistent with the World Health
Organization (WHO) definition of QOL as
“individuals’ perception of their position in life in
the context of the culture and value systems in
which they live and in relation to their goals,
expectations, standards and concerns. It is a broad
ranging concept affected in a complex way by the
person’s physical health, psychological state, level of
independence, social relationships, personal beliefs
and their relationship to salient features of their
environment.”8(p1)
The model development process was informed by
examining existing QOL conceptual models and
frameworks applied to MD and/or non-MD popula-
tions. For example, in a systematic review, Bakas
et al.9 found that the 3 most frequently used HRQOL
models were (1) the Wilson and Cleary model,10 (2)
revised Wilson and Cleary model,11 and (3) WHO
International Classification of Functioning, Disabil-
ity and Health (ICF).12 The revised Wilson and
Cleary HRQOL model illustrates a progression from
biological function to HRQOL through symptoms,
functional status, and general health perceptions;
individual and environmental characteristics are
shown as having an influence throughout this entire
process. This model is useful for identifying physical
determinants of HRQOL; however, it does not pro-
vide a breakdown of the specific components com-
prising QOL and does not capture other types of
determinants of QOL.
The ICF model operationalizes HRQOL in terms
of functioning divided into (1) body functions, (2)
activities, and (3) participation. For example, partici-
pation would include an individual’s ability to engage
in social interactions. Similar to the Wilson and
Cleary models, in the ICF model, an individual’s
health condition, personal factors, and environmental
factors can have an impact on HRQOL. With its
focus on functioning, the ICF model omits other
components of QOL that may be applicable to indi-
viduals with MD, such as mood/affect, perceived con-
trol, stigma, and social support.
After reviewing these and other existing QOL
models, we chose to adapt the NIH Patient-Reported
Outcomes Measurement Information System
(PROMIS) HRQOL framework by adding domains
identified as essential for a comprehensive evaluation
of QOL among individuals with MD. The PROMIS
framework includes 3 broad domains of QOL—
physical, mental, and social13—and has been applied
to many different patient populations. These domains
are consistent with the WHO definition of health as a
“state of complete physical, mental and social well-
being and not merely the absence of disease or infir-
mity.”14 In addition, these broad domains encompass
many of the domains included in other QOL models;
for example, the social domain captures much of the
participation domain in the ICF model.
The CMQM expands the physical domain in the
PROMIS model, which captures fatigue, pain, and
Figure 2 Study process
The flowchart outlines the steps undertaken in the study, including the Delphi process, model
development, and review of existing quality-of-life measures. CMQM 5 Comprehensive Model
ofQuality of Life inMuscular Dystrophy; COSMIN5Consensus-Based Standards for the Selec-
tion of Health Measurement Instruments; MD 5 muscular dystrophy; QOL 5 quality of life.
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sexual functioning, to include the concepts of mobil-
ity, vitality, and personal care (figure 3). These issues
may be of particular concern to individuals with MD
who, by nature of the disease, may lose their mobility
and require assistance with activities of daily living.
The Psychological domain overlaps with the
PROMIS Mental domain and includes mood and
affect, broadly defined to include concepts such as
depression, anxiety, and anger, as well as cognitive
functioning, which may be affected by MD. The
domain was also expanded to include feelings of con-
trol and self-efficacy, as well as uncertainty about the
future. Finally, the Social domain includes compo-
nents similar to those in the PROMIS model (i.e.,
role participation, relatedness/connectedness, social
support); however, it also captures concerns reported
by individuals with MD regarding stigma related to
their disease and concerns about the impact of their
disease on others, especially caregivers.
In addition to characterizing domains of QOL,
the CMQM includes potential determinants and
moderators of QOL. These factors include disease-
related factors, such as the type of MD, age at onset,
time since diagnosis, severity of condition, comorbid-
ities, and family history of MD. Potential moderators
of self-appraisals include support/resources and ex-
pectations/aspirations. Greater access to support and
resources, such as adaptive technology, may help
ameliorate the impact of MD on QOL. Individuals
experiencing greater misalignment between their ex-
pectations/aspirations and their actual abilities as
the disease progresses may experience a greater impact
on their QOL.
The CMQM also incorporates a Bronfenbrenner
ecological systems theory approach15 to account for
contextual factors, including the individual, family,
and community-level factors shown in table 1. The
potential influence of individual and environmental
factors on QOL is also acknowledged by other types
of models, such as the revised Wilson and Cleary
model and the ICF model. Finally, the model ac-
counts for possible changes in QOL across the life
course, consistent with life course models16 and ad-
dressing concerns of stakeholders about capturing
transitions over time in this progressive disease.
QOL construct measures. The literature review revealed
21 articles covering 15 QOL scales (9 adult and 6
pediatric) applied to individuals with MD (table 2).
The content areas and subscales of each scale are
Figure 3 Comprehensive Model of Quality of Life in Muscular Dystrophy
The diagram outlines the domains comprising 3 dimensions of quality of life in MDs (physical, psychological, and social) and the pathways connecting
disease-related factors, support and resources, and expectations to quality of life and well-being. MD 5 muscular dystrophy.
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shown in table e-2, and their psychometric properties
are outlined in table e-3.2–6,17–32
The Medical Outcomes Study 36-Item Short Form
Health Survey emerged as the most frequently used
generic QOL questionnaire among adults with MD33
while the Individualized Neuromuscular Quality of Life
(INQoL) questionnaire was the most frequently used
neuromuscular disease–specific measure for adults.
The most frequently used pediatric measure applied
to MD, the Pediatric Quality of Life Inventory
(PedsQL), assesses QOL among children/adolescents
aged 2 to 18 years with chronic health conditions.34,35
Two neuromuscular disease–specific modules have
been developed for the PedsQL and administered to
children/youth with MD, the Neuromuscular and
Duchenne MD modules.
Considerations in measure selection. In a methodologic
report for the Patient Centered Outcomes Research
Institute, Acaster et al.36 outlined minimum standards
for the design and selection of patient-reported out-
come measures. They indicated the following criteria
should be considered when selecting measures: (1)
content validity, (2) measurement properties and
interpretability, (3) patient burden, and (4) the diver-
sity of samples in which the measurement properties
were established.
Content validity. While some existing QOL measures
(e.g., NeuroQOL, InQoL, PedsQL) include subscales
related to the 3 broad QOL domains (physical, psy-
chological, and social), none captured all of the com-
ponents within these domains identified by
stakeholders in developing the CMQM (figure 3).
Within the physical domain, several measures cap-
tured common symptoms, such as fatigue, pain,
and sleep; however, only the TNO-AZL Question-
naire for Adult’s Quality of Life (TAAQoL)37
included a sexual functioning subscale. In the psycho-
logical domain, while some scales include related con-
cepts, such as autonomy and self-esteem, none
included a self-efficacy subscale, and only the
WHOQOL (World Health Organization Quality of
Life) had a subscale related to perceived control. Over-
all, coverage was generally sparsest in the social
domain. Several scales included subscales designed to
capture overall social functioning or specific roles/daily
activities (e.g., employment, leisure), but did not nec-
essarily include all of the social aspects of QOL out-
lined in the CMQM. For example, none of the
measures captured individuals’ concerns about the
impact of their condition on others. Only disease-
specific measures included questions related to stigma.
Measurement properties. None of the studies reported
on responsiveness of the scale to change in clinical
condition. Very few studies reported on reliability
of the measures among individuals with MD, and
those that did generally reported Cronbach a and/
or parent-child agreement for pediatric meas-
ures2,5,6,17,20–22,31 (table e-3). Validity was primarily
assessed by comparing mean scores of those with
MD to healthy individuals/norms and/or examining
the relationship of the measure with measures of
related constructs.
Patient burden. Patient burden is an important prac-
tical consideration in measurement, particularly when
assessing QOL among individuals who may be ill or
have difficulty in responding because of their condi-
tion. As described above, content validity is necessary
to obtaining a complete picture of the impact of MD
on QOL; however, content validity must be balanced
with considerations of patient burden. Table 2 lists
the number of items included on each measure to
assist researchers and clinicians in assessing the level
of patient burden. Some of the measures, such as the
Child Health Questionnaire, include short forms that
aim to capture the same construct but with fewer
items. In addition, the NeuroQOL is an item bank
that researchers could use to select items appropriate
to their target population.
Diversity of samples. A primary consideration in mea-
sure selection is that the measure is appropriate for,
and has been tested among, the target population. In
terms of age, the review identified 9 measures for adults,
4 for children/adolescents, and one specifically for ado-
lescents. An additional measure, the NeuroQOL, was
Table 1 Factors affecting quality of life among














Beliefs about muscular dystrophy
Cultural perceptions of illness
Community level
Geographic location (region, urban/rural)
Wheelchair accessibility
Availability of muscular dystrophy–related resources and
support
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developed for children and adults, but it has been tested
only among pediatric patients with MD.22
Given variability in disease trajectories and age
ranges for the types of MD (figure 1), the most
appropriate measure differs based on the type of
MD among the target population and whether
the validity of the measure has been assessed in
that group. All but one of the studies using the
pediatric measures focused on individuals with
Duchenne MD.2,3,5,6,17–21,23 The studies of adults
with MD varied more in terms of including indi-
viduals with different types of MD,23,26–28,31,32
although some focused solely on those with myo-
tonic MD.4,24,25,30
Furthermore, the measure should be validated for
the language and culture of the target population to
avoid potential differences in interpretations. For
example, researchers selecting measures for US
studies should note that 13 of the 21 studies assess-
ing QOL in MD were conducted outside the
United States4,6,17,18,21,23,24,26,27,29–32 (table e-3). Sev-
eral measures originally developed in the United
States have English versions tested among non-
MD patients that may also be appropriate for indi-
viduals with MD. However, additional translation
and validation work may be needed to develop cul-
turally equivalent English versions of scales, such as
the TACQOL (TNO-AZL Questionnaire for
Children’s Quality of Life) and TAAQoL, which
include relevant content, but were developed out-
side the United States.
Finally, it should be noted that the current study
focused on measurement of QOL; however, in most
cases, these measures would be used in conjunction
with measures of other constructs, such as functional
status, to fully capture the impact of a treatment or
intervention within a clinical trial or research study.
Similar considerations regarding measurement prop-
erties and burden should be taken when selecting
measures of other constructs.











Child Health Questionnaire17 Generic 28 or 50 1 DU C C C
Life Satisfaction Index for Adolescents18 DS 45 1 DU C C
Pediatric Quality of Life Inventory (PedsQL) Generic
Core Modules6,19,20,35
Generic 23 5 DU C C C
Pediatric Quality of Life Inventory (PedsQL) Duchenne
MD Module5
DS 18 1 DU C C C
Pediatric Quality of Life Inventory (PedsQL)
Neuromuscular Module21
DS 25 1 DU C C
Personal Adjustment and Role Skills Scale2 Generic 28 1 DU C C
Quality of Life in Neurological Disorders (NeuroQOL)22 DS Varies 1 Not specified C C C
TNO-AZL Questionnaire for Children’s Quality of Life
(TACQOL)23
Generic 63 1 DU, LG C C C
Adult
Individualized Neuromuscular Quality of Life (INQoL)24 DS 45 1 MY C C C
Myotonic Dystrophy Health Index25 DS 114 1 MY C C C
Psychosocial Well-Being Questionnaire26 Generic 12 1 B, DI, ED, FSHD,
LG, MY
C C
Quality of Life Profile22 Generic 44 1 B, DI, FSHD, LG,
MY, PR
C C C
36-Item Short Form Health Survey (SF-36)4,24,28–30 Generic 36 5 DU, FSHD, LG, MY C C C
Sickness Impact Profile (SIP, SIP68)26 Generic 68 or
136
1 B, DI, ED, FSHD,
LG, MY
C C C
Subjective Estimation of Quality of Life (SQoL)31 Generic 18 1 B, ED, FSHD, LG,
PR
C C
TNO-AZL Questionnaire for Adult’s Quality of Life
(TAAQoL)23
Generic 45 1 B, DU, LG C C C




1 Not specified C C C
Abbreviations: B 5 Becker; DI 5 distal; DU 5 Duchenne; ED 5 Emery-Dreifuss; FSHD 5 facioscapulohumeral; LG 5 limb girdle; MD 5 muscular dystrophy;
MY 5 myotonic; NMD 5 neuromuscular disease; PR 5 proximal.
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DISCUSSION The current study revealed gaps in ex-
isting models and measures for comprehensively cap-
turing QOL among individuals with MD, suggesting
future avenues for research. None of the measures
captured all components of QOL outlined in the
CMQM, and some concepts, such as concern about
impact on others and expectations/aspirations, were
not included in any measure. Additional scale devel-
opment and evaluation work is needed to fill in these
gaps. The item banking approach to scale develop-
ment and the application of computerized adaptive
assessment for scale administration would be particu-
larly beneficial by allowing the scale to be tailored to
each respondent, thereby minimizing respondent
burden. In addition, the approach can also provide
scores that may be used to compare across different
groups (e.g., healthy vs MD, types of MD, age
groups) through the use of item response theory to
place items on a common metric. The NeuroQOL
item bank used this approach and includes physical,
psychological, and social components of QOL; how-
ever, only the pediatric version was specifically devel-
oped for and tested among individuals with MD.22,38
Beyond expanding existing measures to be more
comprehensive, the item banking and computerized
adaptive assessment approach could be used to develop
brief QOL measures that capture each of the compo-
nents identified by patients and stakeholders as critical,
but are concise enough for administration in settings,
such as clinic visits, where a longer version may not
be feasible. For example, quality of care is often assessed
with functional status measures; however, the develop-
ment of a brief QOL measure would also allow for the
inclusion of QOL in a patient-centered approach to
monitoring quality across the continuum of care for in-
dividuals with MD.
The current study also revealed that measurement-
related research in MD has predominantly focused on
those with Duchenne MD. Eleven of the 21 identi-
fied studies included individuals with Duchenne
MD, although it should be noted that this review
included only English-language studies. Further
research is needed to determine the validity of meas-
ures tested among the Duchenne population for use
with individuals who have other types of MD given
differences in age at onset, severity of symptoms,
and life expectancy across the types of MD (figure 1).
With advancements in treatments and assistive
technology, pediatric patients with MD have longer
life expectancies than in the past. For example, average
life expectancy for children diagnosed with Duchenne
MD has improved from the teens to early 20s in the
past to now extending into the 20s and 30s.39,40 Youth
with MD and their families must now prepare for liv-
ing as an adult with MD and adapt to the challenging
transition from adolescence to adulthood when
adolescents/young adults have a desire for increasing
autonomy and control over their lives, but may face
obstacles to achieving independent living because of
the impact of MD. The existing QOL measures were
generally designed for either children/adolescents or
adults with a few having versions for both. However,
none specifically includes questions designed to address
the transition from adolescence to adulthood. Meas-
ures are needed to understand how individuals and
families adapt to the changes during this transition
and the impact on their QOL.
Finally, a notable absence in the literature was
studies on the responsiveness of QOL measures to
changes in condition for individuals with MD. While
several studies reported on validity, none described
the responsiveness of the scale or identified a clinically
meaningful difference in scores. Only one study had a
prospective longitudinal design and could examine
trajectories of QOL over time, but did not relate
changes in QOL to changes in severity of MD.26
Responsiveness is a key psychometric property
needed for measures to be used in intervention studies
and clinical trials, without which it would be impos-
sible to determine whether a lack of change was
attributable to no treatment effect or simply a non-
responsive scale. Longitudinal studies are needed to
examine responsiveness of QOL scales to change in
individuals with MD and establish clinically mean-
ingful differences regarding overall scale scores and
individual QOL domains.
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It’s Time to Plan for ICD-10, and the AAN Can Help
All health care providers are required to transition to ICD-10 on October 1, 2015. Claims for serv-
ices performed on or after this date with an ICD-9 code will not be processed and payments will be
delayed. The AAN provides information and resources to help you make this a smooth transition,
and has partnered with Complete Practice Resources to provide you with an affordable online pro-
ject management tool to help walk you through each phase of the necessary preparation to ensure
you’re ready. Learn more at AAN.com/view/ICD10 and start your transition today!
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